Letter to the FDA

Home  /  News & Information  /  Current Page

After doing some more research, it turns out that the draft guidance that the FDA proposed related to the FDA’s regulatory requirements applicable to manufacturers of in vitro diagnostic products intended for Research Use Only (RUO) or Investigative Use Only (IUO) might have a potentially negative impact on hemochromatosis patients.

You can read the letter that we sent to the FDA Commissioner here.


%d bloggers like this: